Takeda Pharmaceutical (NYSE:TAK) Company Limited is a global biopharmaceutical firm headquartered in Tokyo, Japan. Founded in 1781 by Chobei Takeda I, the company has grown from a regional apothecary into one of Asia’s largest pharmaceutical enterprises. Takeda’s shares trade on the New York Stock Exchange under the ticker TAK, reflecting its significant presence in international capital markets.
The company focuses on the research, development, manufacturing and commercialization of prescription medicines in several key therapeutic areas, including oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Notable products developed and marketed by Takeda include Entyvio for inflammatory bowel disease and Ninlaro for multiple myeloma, among a broad portfolio that addresses both common and underserved medical needs.
Takeda maintains a robust global R&D infrastructure with research centers and manufacturing facilities across Japan, North America and Europe. In 2019, the company completed its acquisition of Shire, significantly bolstering its rare diseases and gene therapy capabilities. This strategic transaction expanded Takeda’s pipeline and underscored its commitment to innovation through both in-house research and external collaborations.
With operations in more than 80 countries, Takeda serves patients across North America, Europe, Asia-Pacific and emerging markets. Since 2014, President and CEO Christophe Weber has led the company’s efforts to integrate its global footprint and streamline operations. Under his leadership, Takeda continues to pursue sustainable growth through patient-centric strategies, scientific excellence and strategic partnerships.
